Neurocrine Biosciences stock fell after the merger was announced.

The fair value estimate for Lexicon Pharmaceuticals sits at US$3.36, with recent price target moves on the Street leaning on how analysts now frame pilavapadin and the broader risk profile of the ...

The young drugmaker's sickle cell treatment is receiving special consideration from the United States' top drug regulator.

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

A small biopharmaceutical firm was getting a big boost Tuesday after Biogen agreed to buy it for $5.6 billion.

Technical indicators for Pfizer and GSK have turned bullish.

The company's pipeline features almost 40 programs in late-stage clinical testing. These clinical trials are testing new drug candidates and seeking additional approvals for drugs such as Tremfya.

Pharma stocks have, so far, outperformed the markets in 2026. However, as risk around Trump tariffs resurface, analysts ...

Pharma stocks fall as Nifty Pharma drops 3%. Sun Pharma, Cipla slide amid US tariff fears and export risk concerns.

Vertex Pharmaceuticals shares surged Tuesday after the company posted promising results from a clinical trial of a drug to ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best multibagger penny stocks to invest in. On March 31, Recursion ...

ORLANDO, FL / ACCESS Newswire / April 2, 2026 / RedChip Companies will air interviews with Infrastructure Capital ...